The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
|Articles|February 2, 2020
- Pharmaceutical Technology-02-02-2020
- Volume 44
- Issue 2
Biometric Authentication Solution
Werum IT Solutions launched the new K.ME-IN in January 2020, a biometric authentication solution with a wearable Nymi Band device, for its PAS-X Manufacturing Execution System.
Werum IT Solutions launched the new K.ME-IN in January 2020, a biometric authentication solution with a wearable Nymi Band device, for its PAS-X Manufacturing Execution System. Users can now authenticate to systems, devices, and machines via a smart wristband.
Each device is assigned to the user based on their biometric identity and can be worn under all types of protective clothing. When authenticated, the device remains on and transmits the user’s identity until it is removed, all while eliminating the traditional method of entering a username, password, PIN code, or scanning a badge.
In the future, Werum plans to incorporate authentication via iris scan, face recognition, and fingerprint into the device.
Articles in this issue
over 6 years ago
Pre-Clinical: Laying the Right Foundationover 6 years ago
Global Supply Issues Create Challengesover 6 years ago
The Call for a Rapid Responseover 6 years ago
ICH to Revise Quality Risk Management Guidelineover 6 years ago
Brexit: What Happens Next for Pharma?over 6 years ago
Of Serious Concern?over 6 years ago
Best Practices in Using Isolator Technologyover 6 years ago
Data Management Practicesover 6 years ago
Blister Packaging MachineRelated to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.